CRL vs. MEDP, INCY, SYNH, ICLR, UTHR, HSIC, TEVA, RGEN, PEN, and QGEN
Should you be buying Charles River Laboratories International stock or one of its competitors? The main competitors of Charles River Laboratories International include Medpace (MEDP), Incyte (INCY), Syneos Health (SYNH), ICON Public (ICLR), United Therapeutics (UTHR), Henry Schein (HSIC), Teva Pharmaceutical Industries (TEVA), Repligen (RGEN), Penumbra (PEN), and Qiagen (QGEN). These companies are all part of the "medical" sector.
Charles River Laboratories International vs.
Medpace (NASDAQ:MEDP) and Charles River Laboratories International (NYSE:CRL) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations.
Charles River Laboratories International has higher revenue and earnings than Medpace. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
Medpace has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.
In the previous week, Medpace had 2 more articles in the media than Charles River Laboratories International. MarketBeat recorded 10 mentions for Medpace and 8 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.70 beat Medpace's score of 0.39 indicating that Charles River Laboratories International is being referred to more favorably in the news media.
82.5% of Medpace shares are owned by institutional investors. Comparatively, 97.8% of Charles River Laboratories International shares are owned by institutional investors. 20.6% of Medpace shares are owned by insiders. Comparatively, 1.1% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Medpace presently has a consensus target price of $235.50, indicating a potential upside of 29.74%. Charles River Laboratories International has a consensus target price of $267.75, indicating a potential upside of 39.53%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, analysts plainly believe Charles River Laboratories International is more favorable than Medpace.
Medpace has a net margin of 16.81% compared to Charles River Laboratories International's net margin of 12.23%. Medpace's return on equity of 60.42% beat Charles River Laboratories International's return on equity.
Charles River Laboratories International received 148 more outperform votes than Medpace when rated by MarketBeat users. However, 64.39% of users gave Medpace an outperform vote while only 63.16% of users gave Charles River Laboratories International an outperform vote.
Summary
Medpace and Charles River Laboratories International tied by winning 9 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Charles River Laboratories International Competitors List
